| Year |
Citation |
Score |
| 2024 |
Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, ... ... Liu GY, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. The Lancet. Oncology. PMID 38211606 DOI: 10.1016/S1470-2045(23)00579-X |
0.306 |
|
| 2022 |
Chang Z, Zhang Y, Fan J, Zhang L, Liu S, Liu G, Tu J. The potential effects and mechanisms of breast inflammatory lesions on the occurrence and development of breast cancer. Frontiers in Oncology. 12: 932743. PMID 35992864 DOI: 10.3389/fonc.2022.932743 |
0.302 |
|
| 2020 |
Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 32789480 DOI: 10.1001/jamaoncol.2020.2965 |
0.304 |
|
| 2017 |
You C, Peng W, Zhi W, He M, Liu G, Xie L, Jiang L, Hu X, Shen X, Gu Y. Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients. Translational Oncology. 10: 786-792. PMID 28806712 DOI: 10.1016/j.tranon.2017.07.005 |
0.315 |
|
| 2010 |
Wang Y, Li JJ, DI GH, Lu JS, Wu J, Liu GY, Hu XC, Wang ZH, Yang WT, Shao ZM. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 32: 864-7. PMID 21223695 |
0.306 |
|
| Show low-probability matches. |